Psyence Group Inc
Psyence Group Inc., a life science biotechnology company, engages in the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma. It operates in two segments, Clinical Trial Activities and Non-Clinical Trial Activities. The company develops botanical psilocybin-based psychedelic medicine, which works with natural psilocybin products for the h… Read more
Psyence Group Inc (PSYGF) - Net Assets
Latest net assets as of September 2025: $843.69K USD
Based on the latest financial reports, Psyence Group Inc (PSYGF) has net assets worth $843.69K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($895.96K) and total liabilities ($52.28K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $843.69K |
| % of Total Assets | 94.17% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 402.11 |
Psyence Group Inc - Net Assets Trend (2016–2025)
This chart illustrates how Psyence Group Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Psyence Group Inc (2016–2025)
The table below shows the annual net assets of Psyence Group Inc from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $9.54 Million | +180.63% |
| 2024-03-31 | $-11.83 Million | -986.93% |
| 2023-03-31 | $1.33 Million | -50.79% |
| 2022-03-31 | $2.71 Million | +22214.31% |
| 2021-03-31 | $-12.26K | -115.28% |
| 2020-03-31 | $80.25K | -19.19% |
| 2019-03-31 | $99.31K | +186.44% |
| 2018-03-31 | $-114.89K | -21.03% |
| 2017-03-31 | $-94.92K | -55.18% |
| 2016-03-31 | $-61.17K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Psyence Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 30524200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $21.83 Million | 1695.64% |
| Other Comprehensive Income | $737.52K | 57.30% |
| Other Components | $1.95 Million | 151.47% |
| Total Equity | $1.29 Million | 100.00% |
Psyence Group Inc Competitors by Market Cap
The table below lists competitors of Psyence Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nextage Therapeutics Ltd
TA:NXTG
|
$70.01K |
|
TRUBF
PINK:TRUBF
|
$70.10K |
|
Syncona Limited
LSE:SYNC
|
$70.15K |
|
New Mountain Finance Corporation
NASDAQ:NMFC
|
$70.18K |
|
Crossroads Systems Inc
OTCQX:CRSS
|
$69.92K |
|
Margo Caribe Inc
PINK:MRGO
|
$69.91K |
|
Mercer Park Opportunities Corp Ordinary Shares - Class A (Restricted Voting
TO:SPAC-U
|
$69.87K |
|
TEEKAY
MU:TCD
|
$69.82K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Psyence Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -23,881,969 to 1,287,224, a change of 25,169,193.
- Net loss of 400,230 reduced equity.
- Other comprehensive income increased equity by 613,157.
- Other factors increased equity by 24,956,266.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-400.23K | -31.09% |
| Other Comprehensive Income | $613.16K | +47.63% |
| Other Changes | $24.96 Million | +1938.77% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Psyence Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-03-31 | $-0.12 | $0.00 | x |
| 2017-03-31 | $-0.19 | $0.00 | x |
| 2018-03-31 | $-0.23 | $0.00 | x |
| 2019-03-31 | $0.14 | $0.00 | x |
| 2020-03-31 | $0.05 | $0.00 | x |
| 2021-03-31 | $0.00 | $0.00 | x |
| 2022-03-31 | $0.03 | $0.00 | x |
| 2023-03-31 | $0.01 | $0.00 | x |
| 2024-03-31 | $-0.18 | $0.00 | x |
| 2025-03-31 | $0.14 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Psyence Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 8.24x
- Recent ROE (-31.09%) is above the historical average (-69.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.62K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-45.29K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.48K |
| 2019 | -13.42% | 0.00% | 0.00x | 1.74x | $-23.25K |
| 2020 | -23.75% | 0.00% | 0.00x | 1.75x | $-27.08K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-91.28K |
| 2022 | -169.69% | -83031.33% | 0.00x | 1.61x | $-4.87 Million |
| 2023 | -455.87% | -109768.85% | 0.00x | 3.00x | $-6.22 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-67.06 Million |
| 2025 | -31.09% | 0.00% | 0.00x | 8.24x | $-528.95K |
Industry Comparison
This section compares Psyence Group Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $308,328,125,500
- Average return on equity (ROE) among peers: 18.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Psyence Group Inc (PSYGF) | $843.69K | 0.00% | 0.06x | $70.01K |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |